{"entity":{"id":"tqb2450","kind":"drug","name":"TQB2450","aka":[],"tldr":"TQB2450 is an experimental monoclonal antibody from Chia Tai Tianqing Pharmaceutical in phase 3 trials for renal cell carcinoma and non-small-cell lung cancer, aimed at PD-L1 and PD-1.","summary":"TQB2450 is a monoclonal antibody developed by Chia Tai Tianqing Pharmaceutical. Its targets are PD-L1 and PD-1 (the sponsor names PD-L1). The sponsor states: TQB2450 is a humanised monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 binding to PD-1 and B7.1 receptors on T cells, restoring T-cell activity and enhancing immune response. ClinicalTrials.gov describes the intervention as: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potenti. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT04523272 (A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer), in renal cell carcinoma and non-small-cell lung cancer. The largest, NCT04523272, plans to enrol 528 participants (actual) with primary completion was scheduled for 2025-06 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of TQB2450","url":"https://clinicaltrials.gov/search?intr=TQB2450"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["rcc","nsclc"],"sections":[],"technologies":[],"targets":["pdl1","pd1"],"drugs":[],"companies":["sino-biopharm"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04523272","nct05913089"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"monoclonal antibody","mechanism":"TQB2450 is a humanised monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 binding to PD-1 and B7.1 receptors on T cells, restoring T-cell activity and enhancing immune response.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/tqb2450/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"target":[{"id":"cd80","kind":"target","name":"CD80 (B7-1)","route":"/targets/cd80/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}],"company":[{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/"}],"trial":[{"id":"nct05913089","kind":"trial","name":"A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer","route":"/trials/nct05913089/"},{"id":"nct04523272","kind":"trial","name":"A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer","route":"/trials/nct04523272/"}]}}